Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Idoia Bolinaga Ayala

Idoia Bolinaga Ayala

Institutions of which they are part

Predoctoral researcher
Protein kinases in cancer research
Vall Hebron Institut de Recerca
Idoia Bolinaga Ayala

Idoia Bolinaga Ayala

Idoia Bolinaga Ayala

Institutions of which they are part

Predoctoral researcher
Protein kinases in cancer research
Vall Hebron Institut de Recerca

Projects

Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders

IP: Lucas Moreno Martín-Retortillo
Collaborators: Luís Gros Subias, Raquel Andreu Vilarroig, Andrea Vilaplana Blanes, Pablo Velasco Puyó, Laura Murillo Sanjuán, Maria Isabel Benitez Carabante, Aroa Soriano Fernández, Guillem Pons Barcons, Jose Miguel Lizcano De Vega, Maria Cristina Díaz de Heredia Rubio, Maria Luz Uría Oficialdegui, Maria Jose Pérez García, Miguel Segura Ginard, M Mar Mañu Pereira, Lorena Valero Arrese, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Anna Llort Sales, Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders, Raquel Hladun Alvaro, Carlota Aguilera Ordoñez, Adria Molero Valenzuela, Júlia Sansa Girona, Gabriela Guillén Burrieza, Laura Alonso Garcia, Victoria Gutierrez Valle, Idoia Bolinaga Ayala, Josep Roma Castanyer, Sergio Espinosa Gil, Elena Andretta, Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders, Amira Idrizovic
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00638
Duration: 01/01/2022 - 30/06/2025

Related news

Laboratori de Sarcomes Infantils

VHIR drives cancer research with new personalized therapies and advances in biomarkers

On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.

Laboratori de Sarcomes Infantils

New therapeutic target for an aggressive childhood cancer affecting the muscles

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Dr. José Miguel Lizcano i Dr. Sergio Espinosa

Study identifies strategy to avoid resistance to cancer therapy

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

See more

Related professionals

Vanesa Pleguezuelos Hernandez

Vanesa Pleguezuelos Hernandez

Predoctoral researcher
Transfusional Medicine
Read more
Natalia Avani Da Silva

Natalia Avani Da Silva

Medium Grade Technician
Communication Unit
Communication Directorate
Read more
Monica Carreras Burrull

Monica Carreras Burrull

Administrative
Ethics Committees Support Unit (USCE)
External Strategy Directorate
Read more
Mariel Rojas Lora

Mariel Rojas Lora

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.